Celldex Therapeutics Inc $16.15

down -0.27


27/8/2014 04:00 PM  |  NASDAQ : CLDX  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get CLDX Trend Analysis - it has underperformed the S&P 500 by 49%

Partner Headlines

  1. 5 Companies Developing New Cancer Drugs

    Benzinga
  2. 5-Star Biotech Stock Watch: Celldex Therapeutics

    Benzinga
  3. Top Healthcare Movers For June 9, 2014

    Benzinga
  4. Mid-Afternoon Market Update: Markets Head Downward As Commodities Continue ...

    Benzinga
  5. Celldex's Phase 1 Study of CDX-1401 Published in Science Translational ...

    Benzinga
  6. Mid-Afternoon Market Update: Markets Recover Slightly As Healthcare Stocks ...

    Benzinga
  7. Mid-Day Market Update: NASDAQ Tumbles 1.65%; Nu Skin Shares Surge After ...

    Benzinga
  8. Mid-Morning Market Update: Markets Mostly Lower; ReneSola Swings To Q4 ...

    Benzinga
  9. Morning Market Losers

    Benzinga
  10. Earnings Scheduled For March 3, 2014

    Benzinga
  11. Trade of the Day: Long CLDX

    Benzinga
  12. Celldex Therapeutics Prices 7M Share Offering at $24.50/Share

    Benzinga
  13. Celldex Therapeutics Announces 6.5M Share Offering

    Benzinga
  14. Celldex Therapeutics Initiates Accelerated Approval Study of Glembatumumab ...

    Benzinga
  15. Mid-Afternoon Market Update: Markets Turn Back as Momentum Stocks Drop

    Benzinga
  16. Mid-Day Market Update: SeaDrill Drops On Downbeat Earnings; Giant Interactive ...

    Benzinga
  17. Benzinga's Top #PreMarket Losers

    Benzinga
  18. Celldex Therapeutics Presents Positive Phase 2 Rindopepimut Data in Patients ...

    Benzinga
  19. Downside Protection For Regeneron Pharmaceuticals

    Benzinga
  20. Celldex Announces Publication of Preliminary Data from Phase 2 ReACT Study ...

    Benzinga
  21. Mid-Afternoon Market Update: Twitter IPO a Wild Success as Markets Slide

    Benzinga
  22. Celldex Therapeutics' CDX-1127 Well Tolerated and Demonstrates Anti-Tumor ...

    Benzinga
  23. Celldex to Present Dat at SITC, SNO Annual Meetings

    Benzinga
  24. Pharmaceutical Industry Expected To Collect Billions From Obamacare

    Benzinga
  25. Market Wrap For Monday, September 23: Markets Unmoved Despite Kenyan Terror

    Benzinga
  26. Mid-Afternoon Market Update: Celldex Therapeutics Rallies as Pandora Drops

    Benzinga
  27. These ETFs House The Next Biotech Takeover Targets

    Benzinga
  28. Mid-Day Market Update: Sysco Drops On Q4 Results, McEwen Mining Shares ...

    Benzinga
  29. Mid-Morning Market Update: US Markets Mixed, BlackBerry To Explore Strategic ...

    Benzinga
  30. Celldex Announces Expansion of Phase 2 ReACT Study in Recurrent Glioblastoma ...

    Benzinga
  31. Celldex Reports Phase 1 Study Results of CDX-301, Says Data Support Starting ...

    Benzinga
  32. Celldex Therapeutics Announces Full Exercise of Underwriters' Option to ...

    Benzinga
  33. Celldex's CDX-301 Safely Mobilizes Hematopoietic Cells in Phase 1 Study

    Benzinga
  34. UPDATE: Oppenheimer Raises PT to $10 on Celldex Therapeutics on Improved ...

    Benzinga
  35. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celldex ...

    Benzinga
  36. Morning Market Movers

    Benzinga
  37. Benzinga's Top Pre-Market Gainers

    Benzinga
  38. Celldex Posts Positive 3-Year Survival Data from Phase 2 Rindopepimut Program

    Benzinga
  39. CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q)

    GuruFocus
  40. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celldex ...

    Benzinga
  41. UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT on Celldex Therapeutics

    Benzinga
  42. Earnings Scheduled For August 10, 2012

    Benzinga
  43. Social Media Outlook for Thursday May 24 (HNZ, PAY, RIMM, NTAP)

    Benzinga
  44. From Yesterday, Celldex's CDX-011 Demonstrates High Response Rates in Patients ...

    Benzinga
  45. Celldex Therapeutics Added to Nasdaq Biotechnology Index

    Benzinga
  46. Notable Put Options Activity in Celldex Therapeutics

    Benzinga
  47. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  48. Notable Put Options Activity in Celldex Therapeutics

    Benzinga
  49. Benzinga's Microcap Movers for Tuesday January 17, 2012

    Benzinga
Trading Center